Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
3281-3300 of 3,900 trials

Severe Spasticity: Botulinum Toxin Type A Treatment

We are studying the effects and safety of a personalized dose of botulinum toxin type A for individuals with severe spasticity. This trial aims to see how well it works for managing symptoms in the upper and lower limbs.

Spasticity Due to Brain Damage1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesNeurology

Inhaled Sevoflurane for Sedation in Critically Ill Patients

We are studying whether inhaled sevoflurane improves breathing and safety in ICU patients at risk for ARDS compared to standard sedation methods. This research may help us understand better sedation options for these vulnerable patients.

Patients at Risk of Acute Respiratory Distress Syndrome>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicineOtolaryngologyPulmonology

Brain Aneurysms: Acetylsalicylic Acid Study

We are studying whether acetylsalicylic acid can lower the risk of stroke and improve cognitive function in patients undergoing treatment for unruptured brain aneurysms. This trial compares ASA with a placebo to assess its safety and effectiveness.

Unruptured Cerebral Aneurysm>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteNeurology

Labor Induction: Oxytocin vs. Prostaglandins

We are studying whether oxytocin is as safe as prostaglandins for inducing labor in women with an unfavorable cervix. This trial will help us understand the risks and benefits of both methods.

Labor Induction>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesGynecology and Obstetrics

Daratumumab for Monoclonal Gammopathy of Renal Significance

We are investigating how effective Daratumumab is for patients with Monoclonal Gammopathy of Renal Significance in Finland. This study aims to understand its potential benefits for kidney health.

Monoclonal Gammopathy of Renal Significance (MGRS)Safety phase (I)HematologyNephrology

Metastatic Colorectal Cancer: Choosing Chemotherapy

We are exploring a new approach to select between two chemotherapy options for patients with metastatic colorectal cancer. This study will help us understand how well these treatments work and their potential side effects.

MSS/pMMR Metastatic Colorectal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Endoscopic Sleeve Gastroplasty: Impact of Proton Pump Inhibitors

We are studying how proton pump inhibitors affect the success of endoscopic sleeve gastroplasty in people seeking weight loss. We also want to learn about their effects on quality of life and metabolic health.

Obesity1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesGastroenterologyInternal Medicine

CAR T Cell Therapy for Severe Autoimmune Diseases

We are testing a new treatment using engineered immune cells for people with severe autoimmune diseases that haven't improved with standard therapies. This study aims to see if this approach can help manage their condition.

Idiopathic Inflammatory MyopathySystemic Lupus ErythematosusRheumatoid Arthritis>2 yearsSafety phase (I)Rheumatology

Knee Cartilage Damage: UC-MSC Treatment

We are studying a new treatment using stem cells from umbilical cord tissue for people with cartilage damage in the knee. The trial aims to evaluate the safety and effectiveness of this approach.

Knee Cartilage Defect1-2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineOrthopedics and Traumatology

Ataxia-Telangiectasia: N-Acetyl-L-Leucine Study

We are studying whether N-Acetyl-L-Leucine can improve symptoms and quality of life for people with Ataxia-Telangiectasia. The trial will also assess the safety of this treatment.

Ataxia Telangiectasia3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Dexamethasone for Severe Burns

We are studying whether early treatment with dexamethasone can help reduce serious complications and death in patients with severe burns. This trial will also look at its effects on infections and recovery times.

Severe Burns3-6 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineOrthopedics and Traumatology

Tacrolimus Monotherapy for Elderly Kidney Transplant Recipients

We are studying whether using tacrolimus alone can reduce infection risks and improve quality of life for elderly patients after a kidney transplant. This trial compares it to the standard triple medication regimen.

Kidney Transplant Complications>2 yearsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineNephrology

Idiopathic Hypersomnia: TAK-360 Study

We are testing a new medication, TAK-360, for people with idiopathic hypersomnia to see if it helps reduce excessive daytime sleepiness and improve overall condition. The study will also monitor the safety and tolerability of the treatment.

Idiopathic Hypersomnia3-6 monthsEfficacy phase (II)Investigational MedicinesPartially RemoteNeurology

Post-COVID-19 Syndrome: Vericiguat Study

We are investigating whether Vericiguat can improve physical function and reduce fatigue in individuals with post-COVID-19 syndrome compared to a placebo. This study aims to assess various aspects of health and safety related to the treatment.

Post-COVID-19 Syndrome3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteCardiologyInternal MedicinePulmonology

Pancreatic Head Cancer: Neoadjuvant Chemotherapy Study

We are exploring whether giving chemotherapy before surgery helps improve survival for patients with resectable pancreatic head cancer compared to surgery alone. This study aims to find better treatment strategies to reduce early mortality.

Resectable Pancreatic Head Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesOncology

COVID-19: Ibuzatrelvir Study for High-Risk Patients

We are investigating whether ibuzatrelvir can help reduce symptoms and prevent severe illness in non-hospitalized adults and adolescents with COVID-19. This study compares the medication to a placebo to see how effective it is.

COVID-193-6 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInfectious DiseasesInternal Medicine

Advanced NSCLC: Roginolisib with Dostarlimab

We are studying a new treatment combination for patients with advanced non-squamous lung cancer who have not responded to standard therapies. The trial will evaluate safety and early signs of effectiveness.

Advanced Non-Squamous Non-Small Cell Lung CancerSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncologyPulmonology

Multiple Sclerosis Spasticity: BMS-986368 Study

We are evaluating a new oral medication for spasticity in people with multiple sclerosis. The study aims to see if it improves symptoms and overall function compared to a placebo.

Multiple SclerosisMultiple Sclerosis Spasticity3-6 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesPartially RemoteNeurologyRheumatology

Psilocybin for Depression in Cancer Patients

We are studying whether psilocybin can quickly improve depression in people with cancer compared to ketamine and midazolam. The trial will also look at its effects on quality of life and overall well-being.

Depression Related to Cancer3-6 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesOncologyPsychiatry

Solid Cancers: NI-1801 Antibody Study

We are testing a new antibody treatment for patients with solid cancers to see how well it works alone and with other therapies. This study aims to understand its safety and potential benefits.

Malignant Solid Tumor3-6 monthsSafety phase (I)Oncology